The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
DISC-0974 as an anemia-directed therapy in myelofibrosis: rationale and interim RALLY-MF data
Rupali Bhave, MD, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, reviews DISC-0974, a first-in-class anti-hemojuvelin antibody that lowers hepcidin, as an anemia-directed therapy in myelofibrosis. Dr Bhave highlights the rationale for targeting hepcidin and interim data from the ongoing Phase II RALLY-MF trial (NCT05320198) which showed major hemoglobin and transfusion responses and favorable tolerability. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
